Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Shaffer

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
The Lancet. Haematology|December 3, 2025
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 studyMichael Scordo, Miguel-Angel Perales, Audrey Mauguen, et al.
Transplantation and Cellular Therapy|April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 AlterationsMoataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Transplantation and Cellular Therapy|May 25, 2021
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular TherapyCorrado Zuanelli Brambilla, Stephanie M Lobaugh, Josel D Ruiz, et al.
Bone Marrow Transplantation|July 23, 2020
Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantationRichard J Lin, Raymond E Baser, Theresa A Elko, et al.
Blood Advances|December 8, 2020
High progression-free survival after intermediate intensity double unit cord blood transplantation in adultsJuliet N Barker, Sean M Devlin, Kristine A Naputo, et al.
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
The Lancet. Haematology|December 3, 2025
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 studyMichael Scordo, Miguel-Angel Perales, Audrey Mauguen, et al.
Transplantation and Cellular Therapy|April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 AlterationsMoataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Transplantation and Cellular Therapy|May 25, 2021
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular TherapyCorrado Zuanelli Brambilla, Stephanie M Lobaugh, Josel D Ruiz, et al.
Bone Marrow Transplantation|July 23, 2020
Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantationRichard J Lin, Raymond E Baser, Theresa A Elko, et al.
Blood Advances|December 8, 2020
High progression-free survival after intermediate intensity double unit cord blood transplantation in adultsJuliet N Barker, Sean M Devlin, Kristine A Naputo, et al.
JAMA Network Open|May 5, 2026
Hematopoietic Cell Transplant Access and Patient DiversityRachel Cusatis, Jianqun Kou, Caitrin Bupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Pageof 18